Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene
Received 3 February 2009; received in revised form 13 March 2009; accepted 18 March 2009. published online 31 March 2009.
Abstract
The sarco(endo)plasmic reticulum calcium ATPase 2 (SERCA2) transports Ca2+ from cytosol into the sarcoplasmic reticulum (SR) of cardiomyocytes, thereby maintaining the store of releasable Ca2+ necessary for contraction. Reduced SERCA function has been linked to heart failure, and loss of SERCA2 in the adult mammalian heart would be expected to cause immediate severe myocardial contractile dysfunction and death. We investigated heart function in adult mice with an inducible cardiomyocyte-specific excision of the Atp2a2 (Serca2) gene (SERCA2 KO). Seven weeks after induction of Serca2 gene excision, the mice displayed a substantial reduction in diastolic function with a 5-fold increase in the time constant of isovolumetric pressure decay (tau). However, already at 4 weeks following gene excision less than 5% SERCA2 protein was found in myocardial tissue. Surprisingly, heart function was only moderately impaired at this time point. Tissue Doppler imaging showed slightly reduced peak systolic tissue velocity and a less than 2-fold increase in tau was observed. The SR Ca2+ content was dramatically reduced in cardiomyocytes from 4-week SERCA2 KO mice, and Ca2+ transients were predominantly generated by enhanced Ca2+ flux through L-type Ca2+ channels and the Na+–Ca2+ exchanger. Moreover, equivalent increases in cytosolic [Ca2+] in control and SERCA2 KO myocytes induced greater cell shortening in SERCA2 KO, suggesting enhanced myofilament responsiveness. Our data demonstrate that SR-independent Ca2+ transport mechanisms temporarily can prevent major cardiac dysfunction despite a major reduction of SERCA2 in cardiomyocytes.
aInstitute for Experimental Medical Research, Ullevaal University Hospital, 0407 Oslo, Norway
bCenter for Heart Failure Research, University of Oslo, 0407 Oslo, Norway
cDepartment of Cardiology, Ullevaal University Hospital, 0407 Oslo, Norway
dDepartments of Anesthesiology, Physiology and Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
eSchool of Medicine, University of California San Diego, La Jolla, CA 92093-0613, USA
fDepartment of Pediatrics, University of Cincinnati, Children's Hospital Medical Center, Division of Molecular Cardiovascular Biology, Cincinnati, OH 45229-3039, USA
gCardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
Corresponding author. Institute for Experimental Medical Research, Ullevaal University Hospital, Kirkeveien 166, NO-0407 Oslo, Norway. Tel.: +47 23 016800; fax: +47 23016799.